2 days ago
3
MarketBeat
Mon, March 2, 2026 astatine 8:14 AM CST 8 min read
-
Leadership transition: Co‑founder Gordon Sanghera stepped down arsenic CEO with Francis Van Parys appointed arsenic successor portion Sanghera remains an advisor done aboriginal 2027, and absorption is refocusing the merchandise portfolio (discontinuing P2 Solo, pausing Elise) toward integrated systems similar P2i, P24 and Q‑Line.
-
Strong FY2025 maturation and 2026 guidance: Oxford Nanopore delivered 24.2% constant‑currency gross maturation successful FY2025 with applied markets rising to ~34% (clinical +59%, biopharma +30%), and guided FY2026 gross maturation of 21–25% alongside a targeted 62% gross margin.
-
Path to profitability and balance‑sheet strength: reported gross borderline was 58.6% (management’s “see‑through” ~61%), adjusted EBITDA nonaccomplishment improved by £31.2m (26%), and the institution plans adjusted EBITDA breakeven successful 2027 and cash‑flow breakeven successful 2028 portion holding £302.8m of currency and nary debt.
-
Interested successful Oxford Nanopore Technologies plc? Here are 5 stocks we similar better.
Oxford Nanopore Technologies (LON:ONT) utilized its FY 2025 results telephone to outline a enactment transition, reappraisal a twelvemonth of maturation and outgo control, and supply guidance for 2026 alongside commentary connected strategical absorption and merchandise portfolio changes.
The institution marked the departure of co-founder Gordon Sanghera arsenic main enforcement serviceman aft much than 2 decades starring the business. Board representatives said Sanghera volition stay with Oxford Nanopore successful an advisory capableness done aboriginal 2027 to enactment a transition. The committee besides confirmed Francis Van Parys’ archetypal time arsenic CEO, noting helium was gathering the Oxford-based squad and did not enactment successful the call.
→ The Head Fake: Buying the Chinese Stocks Post-Ruling Dip
Sanghera reflected connected Oxford Nanopore’s origins and reiterated the company’s semipermanent imaginativeness “to alteration the investigation of thing by anyone, anywhere.” He highlighted the breadth of the company’s level ambitions beyond DNA and RNA, including proteomics and the imaginable for tiny molecule and chemic sensing implicit time, portion emphasizing that the institution remains aboriginal successful its journey.
Management reported FY 2025 constant-currency gross maturation of 24.2%, described arsenic marginally up of anterior guidance of 20% to 23%. CFO Nick Keher said maturation exceeded 20% crossed each regions connected a constant-currency ground and included a instrumentality to maturation crossed the MinION range, accordant with earlier commentary.
→ MarketBeat Week successful Review – 02/23 - 02/27
On extremity markets, Sanghera and Keher emphasized an accelerating displacement toward applied segments. Life subject probe tools represented 66% of gross and grew 15% successful 2025, which the institution characterized arsenic an outperformance versus competitors amid a hard marketplace backdrop. Applied extremity markets grew faster, led by objective maturation of 59%, with biopharma up 30% and applied concern up 27%. Management said the applied premix accrued to astir 34% from astir 30% twelvemonth implicit year, which they said aligned broadly with expectations acceptable astatine a anterior superior markets update.
English (CA) · 
English (US) · 
Spanish (MX) ·